piperidine, n-butanol, DMF, DCM were purchased from Shanghai Lingfeng. All commercial reagents were used as received.
Analytical RP-HPLC was performed at room temperature on the Shimadzu LC 20
with UV detector SPD-20A using Inertsil ODS-SP column (4.6 x 250 mm, 5 μm, 100 Å). The RP-HPLC gradient was started at 10% of B (CH 3 CN), then increased to 100% of B over 30 min (A: 0.1% TFA in water). Semi-preparative RP-HPLC was performed on the ULTIMAT 3000 Instrument (DIONEX). UV absorbance was measured using a photodiode array detector at 220 and 254 nm. The RP-HPLC gradient was started at 10% of B (CH 3 CN), then increased to 100% of B over 30 min (A: 0.1% TFA in water). 1 H NMR ( 13 C NMR) spectrums were recorded with a Bruker AV600 or Bruker AV400, at 600 (150) or 400 (100) MHz respectively. Chemical shifts are referenced to either tetramethylsilane as an internal standard or the signals resulting from the residual solvent. High resolution mass spectrums were measured with an ABI Q-star Elite.
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Experimental Procedure 1. Solid-phase synthesis of peptidyl resin 2 on Fmoc-hydrazinobenzoyl AM resin Resin loading: Commercially available Fmoc-hydrazinobenzoyl AM resin (800 mg, 0.61mmol/g) was pre-swelled for 20min in DCM in a manual solid phase peptide synthesis vessel (25 mL). Fmoc removal was achieved by 20 % piperidine in DMF (2 × 3 mL, 5 min). The solution was drained and the resin was washed with DMF (6 x 3 mL) and dry DMF (3 mL). Meanwhile, Fmoc-Ala-OH (75 mg, 0.24 mmol) and HATU (91 mg, 0.24 mmol) were dissolved in dry DMF (3 mL). DIEA (120 μL, 0.72 mmol) was added to the DMF solution. After activating for 5 min, the resulting solution was added to the deprotected resin. The mixture was shaken for 2 h. The solvent was drained and the resin was washed with DMF (6 x 3 mL) and dry DMF (3 mL). Then, a mixture of pivalic anhydride (186 μL, 0.96 mmol) and DIEA (500 μL, 2.88 mmol) in dry DMF (3 mL) was added to the resin and agitated for 15 min to cap any unreacted resin sites. The solution was drained, and the resin was washed with DMF (6 x 3 mL). The resin loading was determined to be 0.3 mmol/g in the case of complete reaction of Fmoc-Ala-OH (0.5 equiv) with resin.
The next synthetic steps can use the following general methods until getting peptidyl resin 2.
Method A: Fmoc deprotection
A solution of 20% piperidine in DMF (3 mL) was added to the resin and the resulting suspension was shaken for 5 min. Then the solution was removed from the resin. Again, a solution of 20% piperidine in DMF (3 mL) was added to the resin and the resulting suspension was shaken for another 5 min. The solution was drained and the resin was washed with DMF (6 x 3 mL) and dry DMF (3 mL).
Method B: Coupling of amino acid
Fmoc-Xaa-OH (or Boc-D-N-Me-Phe-OH) (0.96 mmol, 4 eq.) and HATU (365 mg, 0.96 mmol, 4 eq.) were dissolved in dry DMF (3 mL). DIEA (500 μL, 2.88 mmol, 12 eq.) was added to the DMF solution. The mixture was stirred at room temperature for S4 mmol, 1 eq.). The mixture was shaken until a negative Kaiser test was observed (ca.
30 min). Then the solvent was drained and the resin was rinsed with DMF (4 x 3 mL).
Method C: Kaiser test
During the coupling reaction, a few resin beads were taken out and rinsed with DMF (2 x 1 mL). To the resin beads were added 2 drops of a solution of 2,2-Dihydroxyindane-1,3-dione (15 g) and acetic acid (3 ml) in n-butanol (100 ml).
The resulting solution was heated for 3 min at 90 ℃. No change in color of the resin indicated complete reaction. Blue-to black-stained beads indicated the presence of primary amines.
Method D: Chloranil test
A few resin beads were taken out and rinsed with DMF (2 x 1 mL). To the resin were added 2 drops of a 2% solution of acetaldehyde and 2 drops of a 2% solution of chloranil in DMF. The resulting suspension was allowed to stand for 5 min at room temperature. Blue-to green-stained beads indicated the presence of secondary amines.
Synthesis of peptidyl resin 3
Esterification: To a solution of Fmoc-Ile-OH (1.70 g, 4.8 mmol, 20 eq.) in DCM (2 ml) and DMF (2 ml) was added DCC (494 mg, 2.4 mmol, 10 eq.) at 0 o C. The resulting mixture was stirred at 0 o C for 1h and then at room temperature for 1 h. The resulting dicyclohexylurea was separated by centrifuge, and the solvent was transferred to peptidyl resin 2 followed by the addition of DMAP (293mg, 2.4 mmol, 10 eq.). The reaction mixture was shaken at room temperature for 2 h. Then the resin was washed with DCM (2 x 3 mL) and DMF (4 x 3 mL). This process was repeated once.
After esterification, Fmoc-Arg(Pbf)-OH was coupled to the resin according to Method B to provide peptidyl resin 3.
Cyclization
After removal of the Fmoc group from 3 according to Method A, the peptidyl resin was suspended in a solution of Cu(OAc) 2 (40 mg) and pyridine (400 μL) in dry DMF (4 mL). 
Synthesis of analogues 1b-1i
Analogues 1b-1g and 1i were prepared according to the similar procedures used to synthesize Arg 10 -teixobactin (1a). Exceptionally, D-Me 2 Phe-Arg 10 -teixobactin (1h) was achieved according to the following method: min. The solvent was drained from the resin, 30% formaldehyde solution (1.5 ml, 12 mmol, 50 eq.) was added followed by a solution of NaBH 3 CN (302 mg, 4.8 mmol, 20
eq.) in CH 3 CN/H 2 O (3:1, 2 ml). Afterward, the pH of the reaction mixture was adjusted to between 5 and 7 by addition of acetic acid, and the resin was agitated for 11-7.38 (m, 5H), 7.50-7.66 (m, 2H), 7.70-7.82 (m, 2H), 7.90-8.05 (m, 2H), 8.05-8.55 (m, 3H), 8.92-9.25 (m, 1H) 87-3.20 (m, 6H), 3.50-3.83 (m, 8H), 3.90-4.07 (m, 2H), 4.11-4.40 (m, 8H), 4.50-4.68 (s, 1H), 4.97-5.08 (m, 1H), 5.19-5.40 (m, 2H), 6.74-6.90 (s, 2H), 7.20-7.40 (m, 6H), 7.54-7.85 (m, 4H), 7.88-8.30 (m, 8H), 8.38-8.48 (s, 1H), 8.50-8.60 (d, 1H) 
Minimum inhibitory concentration (MIC) assay
MIC assays of teixobactin analogues 1a-1i were determined by using a broth microdilution method according to CLSI 1 . Staphylococcus aureus (ATCC 29213),
Bacillus subtilis (ATCC 6633) and Escherichia coli (ATCC 25922) were acquired as freeze-dried powders from ATCC. The MIC was defined as the lowest concentration of antibiotic which resulted in no visible growth. Meropenem was also tested as drug control. The assay was done in duplicate in three independent runs to confirm results.
S9
Copies of HRMS spectrums and 1 H NMR spectrums of teixobactin analogues Figure S1 . 
